<p>Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4<sup>+</sup>T Response</p>

Abstract

In the present study, we demonstrated that anti-ST2-conjugated nanoparticles can efficiently control lung inflammation in OVA-induced mice by reducing the ability of ILC2s to produce IL-5 and IL-13, thereby reducing CD4+T cells. Our study also demonstrated that the nanoparticle delivery system could improve the performance of anti-ST2, which may be used as a strategic tool to expand the current drug market.